Abstract: The invention provides isolated nucleic acid molecules, designated ABCB9 transporter nucleic acid molecules, which encode novel ABC transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ABCB9 transporter nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ABCB9 transporter gene has been introduced or disrupted. The invention still further provides isolated ABCB9 transporter proteins, fusion proteins, antigenic peptides, anti-ABCB9 transporter antibodies, and screening assays for ABCB9 transporter modulators. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: The invention provides isolated nucleic acid molecules, designated ABCB9 transporter nucleic acid molecules, which encode novel ABC transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ABCB9 transporter nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which an ABCB9 transporter gene has been introduced or disrupted. The invention still further provides isolated ABCB9 transporter proteins, fusion proteins, antigenic peptides, anti-ABCB9 transporter antibodies, and screening assays for ABCB9 transporter modulators. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: Methods and compositions useful in the treatment of amyloidosis and conditions and diseases associated therewith, such as Alzheimer's disease, are provided. The methods involve administering to a subject in need thereof a pharmaceutical composition including one or more agents that modulate PPAR&agr; and/or PPAR&dgr; activity, resulting in an inhibition of &bgr;-amyloid production and/or release from cells of the subject, particularly brain cells.

Abstract: Methods and compositions useful in the treatment of amyloidosis and conditions and diseases associated therewith, such as Alzheimer's disease, are provided. The methods involve administering to a subject in need thereof a pharmaceutical composition including one or more agents that modulate PPAR&agr; and/or PPAR&dgr; activity, resulting in an inhibition of &bgr;-amyloid production and/or release from cells of the subject, particularly brain cells.

Abstract: Methods and compositions are provided for reducing the level of a catecholamine, in particular dopamine, and conjugates thereof, thus reducing catecholaminergic cell toxicity, by increasing a functional activity or increasing expression of ABC transporter polypeptides. ABC transporters serve to extrude dopamine and dopamine conjugates out of the neuron, thus preventing or reducing dopamine-associated toxicity, including cell death. Agents that increase a level of expression, or increase a functional activity, or increase both, of the ABC transporters find utility in preventing or alleviating Parkinson's disease.

Abstract: The invention relates to the discovery that expression of amyloid precursor protein is regulated by the expression of an ABC transporter. The invention therefore provides methods and compositions for modulating amyloid precursor protein expression in a brain cell, thereby preventing or inhibiting pathological &bgr;-amyloid plaque formation in conditions such as Alzheimer's disease.

Abstract: Methods and compositions, useful in the treatment of amyloidosis and conditions and diseases associated therewith, such as Alzheimer's Disease (AD). These methods involve administering to a subject a pharmaceutical composition including one or more agents which modulate APP catabolism and amyloid deposition. Accordingly, the methods and compositions are useful for inhibiting amyloidosis in disorders in which amyloid deposition occurs. The methods are based, at least in part, on modulating catabolism of APP in APP-containing cells through the use of a mobile ionophore, such as carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone, which does not substantially alter the viability of those cells.

Abstract: The invention provides isolated nucleic acid molecules, designated ABCA9 transporter nucleic acid molecules, which encode novel ABC transporter family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing ABCA9 transporter nucleic acid molecules, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which an ABCA9 transporter gene has been introduced or disrupted. The invention further provides isolated ABCA9 transporter proteins, fusion proteins, antigenic peptides, anti-ABCA9 transporter antibodies, and screening assays for ABCA9 transporter modulators. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.

Abstract: Methods and compositions, useful in the treatment of amyloidosis and conditions and diseases associated therewith, such as Alzheimer's Disease (AD). These methods involve administering to a subject a pharmaceutical composition including one or more agents which modulate APP catabolism and amyloid deposition. Accordingly, the methods and compositions are useful for inhibiting amyloidosis in disorders in which amyloid deposition occurs. The methods are based, at least in part, on modulating catabolism of APP in APP-containing cells through the use of a mobile ionophore, such as carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone, which does not substantially alter the viability of those cells.

Abstract: Methods and compositions, useful in the treatment of amyloidosis and conditions and diseases associated therewith, such as Alzheimer's Disease (AD). These methods involve administering to a subject a pharmaceutical composition including one or more agents which modulate APP catabolism and amyloid deposition. Accordingly, the methods and compositions are useful for inhibiting amyloidosis in disorders in which amyloid deposition occurs. The methods are based, at least in part, on modulating catabolism of APP in APP-containing cells through the use of a mobile ionophore, such as carbonyl cyanide p-(trifluoromethoxy)phenylhydrazone, which does not substantially alter the viability of those cells.

Abstract: Methods and compositions, useful in the treatment of amyloidosis and conditions and diseases associated therewith, such as Alzheimer's Disease (AD). These methods involve administering to a subject a pharmaceutical composition including one or more agents which modulate APP catabolism and amyloid deposition. Accordingly, the methods and compositions are useful for inhibiting amyloidosis in disorders in which amyloid deposition occurs. The methods are based, at least in part, on modulating catabolism of APP in APP-containing cells through the use of a mobile ionophore, such as carbonyl cyanide p-(trifluoromethoxy) phenylhydrazone, which does not substantially alter the viability of those cells.